| Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug development.Contemp Clin Trials | PMID 35803494无 PMCID | 2022-Aug | 0.80 | The record describes a methodological paper about statistical design (2-in-1 design) for oncology drug development, not a report of an original randomized clinical trial's efficacy results. It lacks a specific drug intervention, does not report time-to-event efficacy data, and is not a primary result publication. | 待处理 |
| Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.Lancet Oncol | PMID 35810754无 PMCID | 2022-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.Lancet Oncol | PMID 35835135无 PMCID | 2022-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.Lancet Neurol | PMID 35841908无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.ESMO Open | PMID 35843080PMC9434408 | 2022-Aug | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial.Acta Oncol | PMID 35847998无 PMCID | 2022-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.CNS Drugs | PMID 35896943PMC9328182 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration.Indian J Ophthalmol | PMID 35918962PMC9672715 | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis.NEJM Evid | PMID 38319878无 PMCID | 2022-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.NEJM Evid | PMID 38319892无 PMCID | 2022-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.NEJM Evid | PMID 38319896无 PMCID | 2022-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.Vaccine | PMID 35738968PMC9212435 | 2022-Jul-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet | PMID 35908570无 PMCID | 2022-Jul-30 | 0.85 | The study is a randomized, double-blind, phase 3 trial of upadacitinib in axial spondyloarthritis, meeting criteria for oncology (rheumatic disease is sometimes classified under oncology-related conditions, but the primary endpoint is a categorical response, not a time-to-event outcome). The primary efficacy endpoint is the proportion of patients achieving ASAS40 response at week 14, which is a binary outcome, not a time-to-event endpoint such as overall survival, progression-free survival, or any other survival metric analyzed via Kaplan-Meier or hazard ratio. Therefore, it does not meet the inclusion criterion for a time-to-event efficacy endpoint. | 待处理 |
| Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shanghai 12).Radiat Oncol | PMID 35906623PMC9338557 | 2022-Jul-29 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.BMC Pharmacol Toxicol | PMID 35902898PMC9336069 | 2022-Jul-28 | 0.90 | The study is a Phase III randomized trial with a drug intervention (trastuzumab biosimilar) in human oncology (breast cancer). However, the primary endpoint is pathologic complete response (pCR), which is a binary endpoint, not a time-to-event endpoint. The secondary endpoints include ORR and BCS, which are also not time-to-event. No time-to-event outcomes (OS, PFS, DFS, etc.), Kaplan-Meier curves, or hazard ratios are reported in the abstract. | 待处理 |
| Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.Blood Adv | PMID 35413116PMC9327534 | 2022-Jul-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.JAMA | PMID 35881122PMC9327573 | 2022-Jul-26 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Postoperative Diet with an Oligomeric Hyperproteic Normocaloric Supplement versus a Supplement with Immunonutrients in Colorectal Cancer Surgery: Results of a Multicenter, Double-Blind, Randomized Clinical Trial.Nutrients | PMID 35893914PMC9331223 | 2022-Jul-26 | 0.85 | The study is a randomized, phase III trial in colorectal cancer with an original primary result, but it compares two dietary supplements (nutritional interventions) without a drug-containing arm and reports complications/readmissions as primary/secondary outcomes, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. | 待处理 |
| Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.Lancet | PMID 35871814无 PMCID | 2022-Jul-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med | PMID 35658024无 PMCID | 2022-Jul-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J Med | PMID 35857659无 PMCID | 2022-Jul-21 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.Cardiovasc Res | PMID 34358298PMC9302885 | 2022-Jul-20 | 0.95 | The study is not oncology (focus is atrial fibrillation and cardiovascular death, not human malignant neoplasm). Therefore, it does not meet the core oncology eligibility requirement. | 待处理 |
| Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.J Clin Oncol | PMID 35333599PMC9287281 | 2022-Jul-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.J Clin Oncol | PMID 35427190无 PMCID | 2022-Jul-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.JAMA | PMID 35852527PMC9297119 | 2022-Jul-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT.HIV Res Clin Pract | PMID 35938597PMC10029359 | 2022-Jul-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial.Gut Liver | PMID 35791797PMC9289827 | 2022-Jul-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.N Engl J Med | PMID 35660812PMC10040899 | 2022-Jul-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial.Prog Neuropsychopharmacol Biol Psychiatry | PMID 35304155无 PMCID | 2022-Jul-13 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.Nat Commun | PMID 35821019PMC9276725 | 2022-Jul-12 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J Med | PMID 35665782PMC10561652 | 2022-Jul-07 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.Diabetes Care | PMID 35671039PMC9274225 | 2022-Jul-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.BMJ Open | PMID 35798516PMC9263927 | 2022-Jul-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial.Rheumatology (Oxford) | PMID 34730795PMC9258542 | 2022-Jul-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.Rheumatology (Oxford) | PMID 34791107PMC9258590 | 2022-Jul-06 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BrCA Mutation.Ann Surg | PMID 34597010无 PMCID | 2022-Jul-01 | 0.95 | The study is a randomized, Phase III oncology trial, but it lacks a drug-containing intervention (surgical comparison only) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Functional Outcome of Laparoscopic-Assisted Resection Versus Open Resection of Rectal Cancer: A Secondary Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial.Dis Colon Rectum | PMID 34775413无 PMCID | 2022-Jul-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.Mod Rheumatol | PMID 34850095无 PMCID | 2022-Jul-01 | 0.90 | The record is excluded because it is a non-oncology study (rheumatoid arthritis) and lacks a primary/key secondary time-to-event efficacy endpoint as required. | 待处理 |
| Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials.Mod Rheumatol | PMID 34915576无 PMCID | 2022-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.J Clin Oncol | PMID 35271306PMC9242409 | 2022-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.J Clin Oncol | PMID 35290101PMC9242406 | 2022-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study).Am J Cardiol | PMID 35483979无 PMCID | 2022-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.JAMA Oncol | PMID 35552364PMC9100460 | 2022-Jul-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial.JAMA Oncol | PMID 35616948PMC9136674 | 2022-Jul-01 | 0.95 | The study is a randomized Phase 3 trial in oncology (breast cancer) with original results, but it evaluates a non-drug intervention (radiotherapy positioning and fractionation) and the primary efficacy outcome is an acute toxicity endpoint (moist desquamation), not a time-to-event endpoint (like OS, PFS, DFS) requiring Kaplan-Meier or hazard ratio analysis. | 待处理 |
| Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.JAMA Netw Open | PMID 35834251PMC10881221 | 2022-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials.Eur J Dermatol | PMID 36301752无 PMCID | 2022-Jul-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK.Br J Ophthalmol | PMID 34301613PMC9234403 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The perceived barriers and facilitators to implementation of early mobilisation within a multicentre, phase 3 randomised controlled trial: A qualitative process evaluation study.Aust Crit Care | PMID 34321182无 PMCID | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Open vs robot-assisted radical cystectomy (BORARC): a double-blinded, randomised feasibility study.BJU Int | PMID 34657367无 PMCID | 2022-Jul | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.Alzheimers Dement | PMID 34726348PMC9540900 | 2022-Jul | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |